Meditor Group Ltd increased its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 39.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,800,000 shares of the biopharmaceutical company’s stock after buying an additional 1,654,100 shares during the period. Celldex Therapeutics comprises 2.2% of Meditor Group Ltd’s portfolio, making the stock its 8th largest position. Meditor Group Ltd owned 4.64% of Celldex Therapeutics worth $14,326,000 at the end of the most recent reporting period.
Other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Celldex Therapeutics by 16.4% in the first quarter. Vanguard Group Inc. now owns 9,066,763 shares of the biopharmaceutical company’s stock worth $32,731,000 after buying an additional 1,278,206 shares during the period. Renaissance Technologies LLC boosted its position in shares of Celldex Therapeutics by 42.4% in the first quarter. Renaissance Technologies LLC now owns 1,707,927 shares of the biopharmaceutical company’s stock worth $6,166,000 after buying an additional 508,217 shares during the period. State of Wisconsin Investment Board boosted its position in shares of Celldex Therapeutics by 206.3% in the first quarter. State of Wisconsin Investment Board now owns 750,000 shares of the biopharmaceutical company’s stock worth $2,708,000 after buying an additional 505,138 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Celldex Therapeutics by 426.4% in the first quarter. Dimensional Fund Advisors LP now owns 492,547 shares of the biopharmaceutical company’s stock worth $1,778,000 after buying an additional 398,978 shares during the period. Finally, Norges Bank bought a new position in shares of Celldex Therapeutics during the fourth quarter worth approximately $1,248,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.
Celldex Therapeutics, Inc. (CLDX) traded down 0.42% during mid-day trading on Monday, hitting $2.35. The company had a trading volume of 156,801 shares. The company has a 50-day moving average price of $2.48 and a 200 day moving average price of $3.14. Celldex Therapeutics, Inc. has a 12 month low of $2.20 and a 12 month high of $5.02. The firm’s market capitalization is $293.99 million.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.28). Celldex Therapeutics had a negative return on equity of 53.10% and a negative net margin of 1,825.82%. The firm had revenue of $1.53 million during the quarter, compared to analyst estimates of $0.57 million. Equities analysts forecast that Celldex Therapeutics, Inc. will post ($1.11) EPS for the current fiscal year.
WARNING: This article was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://stocknewstimes.com/2017/07/24/celldex-therapeutics-inc-nasdaqcldx-shares-bought-by-meditor-group-ltd.html.
CLDX has been the topic of a number of analyst reports. Zacks Investment Research raised Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Tuesday, July 11th. ValuEngine cut Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 3rd. Jefferies Group LLC reaffirmed a “hold” rating and issued a $3.50 price target (down from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, May 11th. Aegis reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research note on Thursday, June 29th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, June 6th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $6.75.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
